<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR12">
 <label>12.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mol</surname>
    <given-names>PGM</given-names>
   </name>
   <name>
    <surname>Arnardottir</surname>
    <given-names>AH</given-names>
   </name>
   <name>
    <surname>Motola</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Vrijlandt</surname>
    <given-names>PJ</given-names>
   </name>
   <name>
    <surname>Duijnhoven</surname>
    <given-names>RG</given-names>
   </name>
   <name>
    <surname>Haaijer-Ruskamp</surname>
    <given-names>FM</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Post-approval safety issues with innovative drugs: a European cohort study</article-title>
  <source>Drug Saf</source>
  <year>2013</year>
  <volume>36</volume>
  <issue>11</issue>
  <fpage>1105</fpage>
  <lpage>1115</lpage>
  <pub-id pub-id-type="doi">10.1007/s40264-013-0094-y</pub-id>
  <pub-id pub-id-type="pmid">24048690</pub-id>
 </element-citation>
</ref>
